ADVANCE infectious diseases pharmacy and LEAD antimicrobial stewardship in order
to OPTIMIZE the care of patients

  • Home
  • No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection

27 Apr 2020 4:53 PM | Daniel Hawley (Administrator)


Society of Infectious Diseases Pharmacists •  110 E. Schiller St., Suite 230, Elmhurst, IL 60126
(331) 248-7888sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software